This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Mycophenolate mofetil is approved by the US Food and Drug Administration for the treatment of renal allograft rejection, and recently it has received attention as an alternative steroid-sparing agent in dermatology.^1-3 Dose-dependent nausea, vomiting, diarrhea, and abdominal pain are the most commonly encountered adverse effects. Bone marrow suppression and increased risk of infection are the major safety risks, and mycophenolate mofetil is generally thought to be free of hepatotoxic effects. Herein, we describe 2 patients with atopic dermatitis who developed increased levels of serum hepatic transaminases (liver function tests) following an increase in dosage of mycophenolate mofetil.

Report of Cases

Case 1

A 52-year-old woman had a long history of atopic dermatitis previously treated with prednisone and cyclosporine. Her medications included topical pimecrolimus, conjugated estrogen, fexofenadine, cetirizine, and valsartan. She denied use of alcohol or any herbal or over-the-counter medications. Her baseline levels of serum hepatic transaminases were within the reference range, and her serologic . . . [Full Text of this Article]

Case 2

Comment

AUTHOR INFORMATION
Basil Hantash, MD, PhD; David Fiorentino, MD, PhD

RELATED ARTICLES

Mycophenolate Mofetil as an Effective Corticosteroid-Sparing Therapy for Recalcitrant Dermatomyositis
Johnathon C. Edge, J. David Outland, Jennifer R. Dempsey, and Jeffrey P. Callen
Arch Dermatol. 2006;142(1):65-69.
ABSTRACT | FULL TEXT  

Improvement in Dermatomyositis Rash Associated With the Use of Antiestrogen Medication
Danya Sereda and Victoria P. Werth
Arch Dermatol. 2006;142(1):70-72.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prevention of Osteoporosis Associated With Chronic Glucocorticoid Therapy
Heffernan et al.
JAMA 2006;295:1300-1303.
FULL TEXT  

The Era of Cooperation
Heffernan
Arch Dermatol 2006;142:93-95.
FULL TEXT